Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity, Morbid | 5 | 2022 | 50 | 2.420 |
Why?
|
| Bariatric Surgery | 4 | 2022 | 37 | 1.790 |
Why?
|
| Gastric Bypass | 2 | 2021 | 17 | 1.430 |
Why?
|
| Splenectomy | 2 | 2020 | 43 | 1.380 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2020 | 94 | 1.300 |
Why?
|
| Bariatrics | 1 | 2022 | 1 | 0.810 |
Why?
|
| Frailty | 1 | 2022 | 19 | 0.790 |
Why?
|
| Hypoglycemia | 1 | 2021 | 33 | 0.740 |
Why?
|
| Certification | 1 | 2016 | 15 | 0.540 |
Why?
|
| Educational Measurement | 1 | 2016 | 111 | 0.510 |
Why?
|
| General Surgery | 1 | 2016 | 53 | 0.500 |
Why?
|
| Internship and Residency | 1 | 2016 | 224 | 0.430 |
Why?
|
| Retrospective Studies | 7 | 2022 | 2433 | 0.410 |
Why?
|
| Humans | 12 | 2022 | 26827 | 0.290 |
Why?
|
| Adult | 7 | 2021 | 7383 | 0.240 |
Why?
|
| Postoperative Complications | 3 | 2022 | 604 | 0.240 |
Why?
|
| Cetuximab | 1 | 2021 | 20 | 0.190 |
Why?
|
| Camptothecin | 1 | 2021 | 15 | 0.190 |
Why?
|
| Patient Discharge | 1 | 2022 | 97 | 0.190 |
Why?
|
| Appendiceal Neoplasms | 1 | 2021 | 5 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2021 | 2264 | 0.190 |
Why?
|
| Risk Factors | 3 | 2021 | 2011 | 0.190 |
Why?
|
| Bevacizumab | 1 | 2021 | 93 | 0.180 |
Why?
|
| Length of Stay | 1 | 2022 | 215 | 0.180 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2021 | 31 | 0.180 |
Why?
|
| Male | 7 | 2021 | 12870 | 0.180 |
Why?
|
| Spleen | 1 | 2020 | 109 | 0.170 |
Why?
|
| Recurrence | 1 | 2020 | 316 | 0.170 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 400 | 0.170 |
Why?
|
| Female | 7 | 2021 | 14463 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 133 | 0.170 |
Why?
|
| Chronic Disease | 1 | 2020 | 263 | 0.170 |
Why?
|
| Venous Thromboembolism | 1 | 2021 | 132 | 0.160 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 74 | 0.160 |
Why?
|
| Aged | 5 | 2021 | 5167 | 0.160 |
Why?
|
| Anastomotic Leak | 1 | 2018 | 9 | 0.160 |
Why?
|
| Pancreatic Fistula | 1 | 2018 | 14 | 0.160 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 42 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2018 | 38 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2019 | 143 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 367 | 0.150 |
Why?
|
| Middle Aged | 5 | 2021 | 6818 | 0.150 |
Why?
|
| Prospective Studies | 1 | 2021 | 1217 | 0.140 |
Why?
|
| Mutation | 1 | 2021 | 817 | 0.140 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 125 | 0.140 |
Why?
|
| Wisconsin | 1 | 2016 | 8 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2016 | 162 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2015 | 87 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2016 | 204 | 0.120 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 507 | 0.100 |
Why?
|
| Enbucrilate | 1 | 2009 | 1 | 0.080 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2009 | 16 | 0.080 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 39 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 2009 | 45 | 0.080 |
Why?
|
| Sex Factors | 2 | 2021 | 446 | 0.080 |
Why?
|
| Leucovorin | 1 | 2021 | 15 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2021 | 52 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2021 | 59 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 104 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 38 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 213 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 189 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2021 | 298 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 250 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2018 | 37 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 377 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2018 | 587 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 759 | 0.030 |
Why?
|
| United States | 1 | 2021 | 2033 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 1927 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 107 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2009 | 472 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2009 | 980 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2009 | 1091 | 0.020 |
Why?
|
| Child | 1 | 2009 | 2147 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 2581 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 2957 | 0.010 |
Why?
|